Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death.
Hypoxia and the acquisition of a glycolytic phenotype are intrinsic features of the tumor microenvironment. The hypoxia inducible factor-1alpha (HIF-1alpha) pathway is activated under hypoxic conditions and orchestrates a complex transcriptional program that enhances cell survival. Although the consequences of HIF-1alpha inactivation in cancer cells have been widely investigated, only a few studies have addressed the role of HIF-1alpha in the survival of cancer cells endowed with different glycolytic capacities. In this study, we investigated this aspect in ovarian cancer cells. Hypoxia-induced toxicity was increased in highly glycolytic cells compared with poorly glycolytic cells; it was also associated with a sharp decrease in intracellular ATP levels and was prevented by glucose supplementation. Stable HIF-1alpha silencing enhanced hypoxia-induced cell death in vitro due to a lack of cell cycle arrest. Tumors bearing attenuated HIF-1alpha levels had similar growth rates and vascularization as did controls, but tumors showed higher proliferation levels and increased necrosis. Moreover, tumors formed by HIF-1alpha deficient cells had higher levels of lactate and lower ATP concentrations than controls as shown by metabolic imaging. The findings that such metabolic properties can affect the survival of cancer cells under hypoxic conditions and that these properties contribute to the determination of the consequences of HIF-1alpha inactivation could have important implications on the understanding of the effects of anti-angiogenic and HIF-1alpha-targeting drugs in cancer.
Favaro
Elena
E
Department of Oncology and Surgical Sciences, Oncology Section, University of Padova, Padova, Italy.
Nardo
Giorgia
G
Persano
Luca
L
Masiero
Massimo
M
Moserle
Lidia
L
Zamarchi
Rita
R
Rossi
Elisabetta
E
Esposito
Giovanni
G
Plebani
Mario
M
Sattler
Ulrike
U
Mann
Thomas
T
Mueller-Klieser
Wolfgang
W
Ciminale
Vincenzo
V
Amadori
Alberto
A
Indraccolo
Stefano
S
D000818:Animals; D016923:Cell Death; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D020868:Gene Silencing; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D016086:Lentivirus; D051379:Mice; D016513:Mice, SCID; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology*; D010641:Phenotype; D034741:RNA, Small Interfering / Q000378:metabolism
D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D034741:RNA, Small Interfering
Science. 2006 Jun 16;312(5780):1650-3
16728594
Nat Rev Cancer. 2004 Nov;4(11):891-9
15516961
Cancer Res. 2002 Nov 1;62(21):6099-107
12414634
Mol Cancer Res. 2006 Sep;4(9):601-5
16940159
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1341-51
16516853
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4216-21
16537511
Cell Metab. 2006 Mar;3(3):187-97
16517406
Nature. 1996 Jan 4;379(6560):88-91
8538748
Cell Cycle. 2004 Jul;3(7):853-4
15190211
Oncogene. 1998 Dec 31;17(26):3401-15
10030664
Nat Rev Cancer. 2003 Oct;3(10):721-32
13130303
Am J Pathol. 2003 Apr;162(4):1283-91
12651620
Cancer Res. 2000 Aug 1;60(15):4010-5
10945599
Cancer Res. 1999 Sep 15;59(18):4525-8
10493500
Radiother Oncol. 2004 Aug;72(2):221-30
15297140
Eur J Cancer. 2006 Jul;42(10):1475-83
16759848
Cancer Res. 2005 Apr 15;65(8):3171-8
15833847
J Natl Cancer Inst. 1995 Jan 18;87(2):117-22
7707382
Cancer Cell. 2004 Dec;6(6):553-63
15607960
Cancer Res. 1999 Nov 15;59(22):5830-5
10582706
Cancer Cell. 2003 Jan;3(1):75-88
12559177
Biomol Eng. 2002 Feb;18(6):249-62
11841946
Cell Death Differ. 2003 Jul;10(7):823-32
12815465
Curr Med Chem. 2004 Aug;11(16):2195-204
15279558
J Clin Oncol. 2002 Jan 15;20(2):379-87
11786564
Nat Rev Cancer. 2002 Jan;2(1):38-47
11902584
Cancer Res. 2005 Aug 15;65(16):7249-58
16103076
Radiother Oncol. 2006 Nov;81(2):130-5
16973228
Mol Cell Biol. 2003 Jan;23(1):359-69
12482987
Exp Cell Res. 1997 May 1;232(2):361-70
9168813
EMBO J. 2004 May 5;23(9):1949-56
15071503
Biochem Pharmacol. 2002 Sep;64(5-6):889-92
12213583
J Clin Pathol. 2004 Oct;57(10):1009-14
15452150
Cancer Lett. 2002 Feb 25;176(2):215-23
11804750
Cancer Cell. 2003 Aug;4(2):133-46
12957288
J Biol Chem. 1999 Apr 30;274(18):12567-75
10212235
Science. 1956 Aug 10;124(3215):269-70
13351639
Cell Metab. 2006 Mar;3(3):177-85
16517405
FEBS Lett. 1998 Nov 13;439(1-2):168-72
9849900
J Biol Chem. 2004 Feb 6;279(6):4305-12
14627695
Nat Med. 2005 Sep;11(9):992-7
16127434
Hum Gene Ther. 2005 Aug;16(8):957-70
16076254
J Natl Cancer Inst. 2004 Jun 16;96(12):946-56
15199114
Ann Med. 2004;36(7):530-9
15513303
J Clin Oncol. 2007 Jul 10;25(20):2902-8
17617521
Nature. 1998 Jul 30;394(6692):485-90
9697772
Nature. 2005 Dec 15;438(7070):967-74
16355214
Clin Cancer Res. 2001 Jun;7(6):1661-8
11410504
Cancer Res. 2005 May 15;65(10):4147-52
15899805
J Cell Biochem. 2003 Oct 15;90(3):548-60
14523989
Gene. 2005 Apr 25;350(1):89-98
15794924
Cancer Cell. 2007 Apr;11(4):335-47
17418410
Cancer Res. 2006 Apr 1;66(7):3639-48
16585189
Pediatr Res. 1990 Feb;27(2):186-90
2314949
Nature. 2006 May 25;441(7092):437-43
16724055